Halozyme Therapeutics (HALO) EBIT: 2009-2025
Historic EBIT for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to $217.9 million.
- Halozyme Therapeutics' EBIT rose 33.53% to $217.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $737.4 million, marking a year-over-year increase of 54.59%. This contributed to the annual value of $551.5 million for FY2024, which is 63.36% up from last year.
- Halozyme Therapeutics' EBIT amounted to $217.9 million in Q3 2025, which was up 7.65% from $202.4 million recorded in Q2 2025.
- In the past 5 years, Halozyme Therapeutics' EBIT ranged from a high of $217.9 million in Q3 2025 and a low of $34.1 million during Q2 2022.
- For the 3-year period, Halozyme Therapeutics' EBIT averaged around $131.9 million, with its median value being $117.2 million (2024).
- Per our database at Business Quant, Halozyme Therapeutics' EBIT skyrocketed by 1,674.15% in 2021 and then plummeted by 63.39% in 2022.
- Halozyme Therapeutics' EBIT (Quarterly) stood at $56.5 million in 2021, then skyrocketed by 31.80% to $74.5 million in 2022, then spiked by 35.60% to $101.0 million in 2023, then skyrocketed by 73.70% to $175.5 million in 2024, then surged by 33.53% to $217.9 million in 2025.
- Its last three reported values are $217.9 million in Q3 2025, $202.4 million for Q2 2025, and $141.5 million during Q1 2025.